WO2009007137A2 - Composition pharmaceutique pour application topique de composés difficilement solubles - Google Patents

Composition pharmaceutique pour application topique de composés difficilement solubles Download PDF

Info

Publication number
WO2009007137A2
WO2009007137A2 PCT/EP2008/006067 EP2008006067W WO2009007137A2 WO 2009007137 A2 WO2009007137 A2 WO 2009007137A2 EP 2008006067 W EP2008006067 W EP 2008006067W WO 2009007137 A2 WO2009007137 A2 WO 2009007137A2
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical formulation
formulation according
weight
oil
methyl
Prior art date
Application number
PCT/EP2008/006067
Other languages
English (en)
Other versions
WO2009007137A3 (fr
Inventor
Karin Hoffmann
Hartwig Steckel
Original Assignee
Intendis Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intendis Gmbh filed Critical Intendis Gmbh
Priority to AU2008274507A priority Critical patent/AU2008274507A1/en
Priority to JP2010515429A priority patent/JP2010532778A/ja
Priority to CA 2692482 priority patent/CA2692482A1/fr
Priority to CN200880023951A priority patent/CN101730522A/zh
Priority to BRPI0814043A priority patent/BRPI0814043A2/pt
Priority to EP08785020A priority patent/EP2182918A2/fr
Publication of WO2009007137A2 publication Critical patent/WO2009007137A2/fr
Publication of WO2009007137A3 publication Critical patent/WO2009007137A3/fr
Priority to IL202178A priority patent/IL202178A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

  • composition for topical application of poorly soluble compounds are provided.
  • Topically administered active substances are mainly used to treat the redness, swelling, itching and discomfort of psoriasis, atopic dermatitis and other pathologies of the skin.
  • the majority of such active drug substances exhibit poor solubility in standard solvents, such as water. Poor solubility in the context of this application means that the solubility of the compound in water is 20 mg/l or less at 20 0 C.
  • Glucocorticosteroids, steroids, calcineurin inhibitors, vitamin D analoques, retinoids, immunosuppressants, antimycotics, antiinfectives, estrogens, androgens, fumaric acid esters are typical drug classes for topical administration with such low water solubility.
  • WO 03/082827 examples for such poorly soluble compounds are provided e.g. in WO 03/082827 or WO 2006/050998.
  • One example is the non-steroidal active substance having the chemical name (R)-1 ,1 ,1-Trifluoro-4-(5-fluoro-2,3-dihydrobenzofuran-7-yl)-4-methyl-2- ⁇ [(2-methyl-5-quinolyl)amino]methyl ⁇ pentan-2-ol, the empirical formula of which is C 25 H 26 F 4 N 2 O 2 , having a molecular weight of 462,5.
  • This is the compound according to example 1 of WO 2006/050998 (hereinafter Ex1/998).
  • Said compound is a crystalline, non-polymorphic yellowish-to-green powder that is insoluble in water, only slightly soluble in hexane and moderately soluble in ethyl alcohol. It has very poor solubility in standard cream and ointment vehicles being in use for the topical administration, such as petrolatum and mineral oils. Commercially, topically administered drug products are available as solutions, suspensions, creams and ointments.
  • U.S. Pat. No. 3,892,856 describes the use of corticosteroids dissolved in polyethylene glycol and emulsified into an oleaginous base.
  • Another option to present poorly water-soluble compounds for patient use is the formulation of an oil-in-water type formulation containing the active compound in suspended form.
  • the present invention provides a formulation which contains a poorly water soluble pharmaceutically active compound at a concentration of 50 mg per 100 g formulation or above.
  • the solubility is achieved by a mixture of solvents as described below.
  • the formulation as described below as well as in claim 1 may be used as a base formulation to generate a cream, an ointment, a spray, a foam or an oleogel.
  • the base formulation contains oleyl alcohol, cetearyl octanoate and a vegetable oil in addition to one or more poorly soluble pharmaceutical compounds.
  • One embodiment of the invention is therefore a pharmaceutical formulation (base formulation) containing at least one pharmaceutically active compound as well as a) oleyl alcohol, b) cetearyl octanoate and c) a vegetable oil.
  • the solubility of at least one of the pharmaceutically active compounds in water is 20 mg/l or less at 20 0 C. In an even more preferred embodiment the solubility of at least one of the pharmaceutically active compounds in water is 2 mg/l or less at 2O 0 C, or even 1 mg/l or less at 20°C.
  • glucocorticosteroids • glucocorticosteroids, steroids, calcineurin inhibitors, vitamin D analoques, retinoids, immunosuppressants, antimycotics, antiinfectives, estrogens, androgens, fumaric acid esters
  • glucocorticoids including but not limited to betametasone, clobetasol, dexametasone, prednicarbate, clocortolone, mometasone, methylprednisolone, esters and salts thereof
  • antimycotic drug substances including but not limited to bifonazole, clotrimazole, itraconazole, fluconazole, terbinafine • a vitamin D analogue, including but not limited to Calcipotriol, Calcitriol, Tacalcitol
  • corticosteroids such as prednisone or fludrocortisone
  • calcineurin inhibitors such as tacrolimus or pimecrolimus.
  • the base formulation contains 2 to 50 % (by weight) of oleyl alcohol, preferably 5 to 20 %.
  • the base formulation contains 2 to 50 % (by weight) of cetearyl octanoate, preferably 5 to 20 %.
  • the base formulation contains 2 to 50 % (by weight) of vegetable oil, preferably 5 to 20 %.
  • vegetable oil examples of such vegetable oiis but not limited to these are soybean oil, olive oil, sesame oil, or peanut oil. It has to be understood that the vegetable oil may be a mixture of different vegetable oils. Preferably the vegetable oil is soybean oil.
  • the base formulation described above may be formulated into an oil-in-water cream.
  • Such cream formulation is characterized in that it may contain a high content of aqueous phase (the non-solvent phase) of about 60%, in which stabilization of said two phase system is obtained by using polymeric stabilizers rather than surfactants.
  • aqueous phase the non-solvent phase
  • surfactants typically exert an irritating effect on skin while the formulation described here omits the use of high amounts of surfactants.
  • the oil-in-water cream formulation described here shows an obviously higher drug release rate and better in- vivo efficacy than observed for a fatty ointment composition which is normally used to achieve a high dermal penetration of the drug substance as a result of the occlusivity of such a vehicle.
  • the oil-in-water cream is stable, produces an effective biological activity and was found to be non-irritating to the skin when applied.
  • One further embodiment of the invention is therefore a pharmaceutical formulation in form of a oil-in-water cream formulation containing at least one pharmaceutically active compound as well as a) oleyl alcohol, b) cetearyl octanoate and c) a vegetable oil d) propylene glycol e) glycerol.
  • solubility of at least one of the pharmaceutically active compounds in water is 20 mg/l or less at 20 0 C.
  • the oil-in-water cream formulation contains 3 to 15 % (by weight) of oleyl alcohol, preferably 5 to 10 %. In another embodiment of the invention the oil-in-water cream formulation contains 2 to 15 % (by weight) of cetearyl octanoate, preferably 3 to 10 %. In a still further embodiment of the invention the oil-in-water cream formulation contains 3 to 15 % (by weight) of vegetable oil, preferably 4 to 6 %.
  • oil-in-water cream formulation contains 4 to 10 % (by weight) of glycerol (85%), preferably approximately 8%. In a still further embodiment of the invention the oil-in-water cream formulation contains 4 to 10 % (by weight) of propylene glycol, preferably approximately 8%.
  • oils examples include soybean oil, olive oil, sesame oil, castor oil or peanut oil. It has to be understood that the vegetable oil may be a mixture of different vegetable oils. Preferably the vegetable oil is soybean oil. Cream formulations according to the present invention may furthermore contain medium-chained triglycerides, mineral oils, cyclomethicone, stearyl alcohol, butylated hydroxytoluene, macrogolglycerolhydroxystearate, povidone, acrylic acid copolymer, hydroxyethylcellulose, acrylic acid, trometamol, or mixtures thereof.
  • Oleogel formulation The base formuiation described in the beginning may also be turned into an oleogel formulation.
  • Such oleogel formulation is characterized in that it is a gelated viscous formulation of the described lipid blend as herein described.
  • One further embodiment of the invention is therefore a pharmaceutical formulation in form of an oleogel formulation containing at least one pharmaceutically active compound as well as a) oleyl alcohol, b) cetearyl octanoate and c) a vegetable oil d) silicon dioxide or aluminium stearate.
  • the solubility of at least one of the pharmaceutically active compounds in water is 20 mg/l or less at 20 0 C.
  • the oleogel formulation contains 10 to 40 % (by weight) of oleyl alcohol, preferably 15 to 30 %.
  • the oleogel formulation contains 5 to 40 % (by weight) of cetearyl octanoate, preferably 10 to 30 %.
  • the oleogel formulation contains 10 to 30 % (by weight) of vegetable oil, preferably 15 to 20 %.
  • the oleogel formulation contains 3 to 10 % (by weight) of silicone dioxide, preferably 4 to 5 %, or 2 to 8 % (by weight) of aluminium stearate, preferably 3 to 6 %.
  • oils examples include soybean oil, olive oil, sesame oil, castor oil or peanut oil. It has to be understood that the vegetable oil may be a mixture of different vegetable oils. Preferably the vegetable oil is soybean oil. Oleogel formulations according to the present invention may furthermore contain medium-chained triglycerides, mineral oils, cyclomethicone, or mixtures thereof.
  • the base formulation described in the beginning may also be turned into a spray formulation.
  • Such spray formulation is characterized in that it contains the pharmaceutically active compound in dissolved state and is stored in a container from which it may be sprayed to the skin of a patient.
  • One further embodiment of the invention is therefore a pharmaceutical formulation in form of a spray formulation containing at least one pharmaceutically active compound as well as a) oleyl alcohol, b) cetearyl octanoate, c) a vegetable oil and d) mineral oil.
  • the solubility of at least one of the pharmaceutically active compounds in water is 20 mg/l or less at 20 0 C.
  • the spray formulation contains 10 to 50 % (by weight) of oleyl alcohol, preferably 10 to 40 %.
  • the spray formulation contains 10 to 50 % (by weight) of cetearyl octanoate, preferably 20 to 40 %.
  • the spray formulation contains 10 to 50 % (by weight) of vegetable oil, preferably 16 to 30 %.
  • the spray formulation contains 2 to 15 % (by weight) of mineral oil, preferably 4 to 15 %.
  • vegetable oils examples include soybean oil, olive oil, sesame oil, castor oil or peanut oil. It has to be understood that the vegetable oil may be a mixture of different vegetable oils. Preferably the vegetable oil is soybean oil.
  • Spray formulations may furthermore contain medium-chained triglycerides, cyclomethicone, or mixtures thereof.
  • the base formulation described in the beginning may also be turned into a foam formulation.
  • foam formulation is characterized in that it contains the pharmaceutically active compound in dissolved state and is contained in a pressurized can from which the foam is created upon release by evaporation of the prope ⁇ ant.
  • One further embodiment of the invention is therefore a pharmaceutical formulation in form of a foam formulation containing at least one pharmaceutically active compound as well as a) oleyl alcohol, b) cetearyl octanoate and c) a vegetable oil d) propylene glycol e) glycerol f) a propellant.
  • the solubility of at least one of the pharmaceutically active compounds in water is 20 mg/l or less at 2O 0 C.
  • the lipid phase of the foam formulation contains 2 to 15 % (by weight) of oleyl alcohol, preferably 3 to 10 %.
  • the lipid phase of the foam formulation contains 2 to 10 % (by weight) of cetearyl octanoate, preferably 3 to 5 %.
  • the lipid phase of the foam formulation contains 2 to 10 % (by weight) of vegetable oil, preferably 3 to 5 %.
  • the foam formulation contains 2 to 10 % (by weight) of glycerol (85%), preferably 4 to 8 %.
  • the foam formulation contains 2 to 10 % (by weight) of propylene glycol, preferably 4 to 10 %.
  • the foam formulation contains 2 to 10 % (by weight) of propellant, preferably 6 to 8 %.
  • propellants are compounds that are gases under atmospheric pressure at room temperature but that may by liquiefied at room temperature by pressurization.
  • propellants include hydrocarbons such as propane, butane, isobutane or a mixture of these; a hydrofluoroalkane such as heptafluoropropane or tetrafluoro- ethane as well as dimethylether, or mixtures thereof.
  • examples of vegetable oils include soybean oil, olive oil, sesame oil, castor oil or peanut oil. It has to be understood that the vegetable oil may be a mixture of different vegetable oils.
  • the vegetable oil is soybean oil.
  • Foam formulations may furthermore contain macrogolglycerolhydroxystearate, macrogol-400-stearate, methylcellulose, xanthan gum or mixtures thereof.
  • Alternative hydrophiiic polymers acrylic acid copolymer, acrylic acid, cellulose ethers, such as hydroxyethylmethylcellulose, hydroxyethylcellulose and methylcellulose, polyvinylalcohol, polyvinylpyrollidone, xanthan gum, alginates, chitosan.
  • An oily spray by definition of the invention should be understood as a liquid, sprayable formulation containing the active drug in dissolved state and is composed of the core formulation containing at least a vegetable oil, oleyl alcohol and cetearylocta noate .
  • An oleogel by definition of the invention should be understood as a gelated, viscous formulation containing the active drug in dissolved state and is composed of the core formulation containing at least a vegetable oil, oleyl alcohol and cetearyloctanoate where the gelling is obtained by addition of a thickening agent, such as e.g. silicon dioxide and/or aluminium stearate.
  • a thickening agent such as e.g. silicon dioxide and/or aluminium stearate.
  • a foam by definition of the invention should be understood as formulation containing the active drug in dissolved state and is composed of the core formulation containing at least a vegetable oil, oleyl alcohol and cetearyloctanoate, and an aqueous phase composed as in the examples.
  • the foam is created upon release from a pressurized can and by evaporation of the liquefied propellant (the liquefied propellant being a hydrocarbon propellant such as propane, butane, isobutane or a mixture of these; a hydrofluoroalkane such as heptafluoropropane or tetrafluoroethane; dimethylether or mixtures of these)
  • the liquefied propellant being a hydrocarbon propellant such as propane, butane, isobutane or a mixture of these; a hydrofluoroalkane such as heptafluoropropane or tetrafluoroethane; dimethylether or mixtures of these
  • the formulations according to the present invention may be manufactured according to the methods well-known to the expert in the art. Such manufacturing technologies are also well described in the literature, as 'Pharmaceutical Emulsions and Suspensions' by Francoise Nielloud & Gilberte Marti-Mestres, Marcel Dekker, New York and 'Food Emulsions' - Food Science and Technology, by Stig Friberg, Kare Larsson & Stig E. Friberg, Marcel Dekker, New York.
  • composition containing at least one pharmaceutically active compound as well as a) oleyl alcohol, b) cetearyl octanoate and c) a vegetable oil.
  • composition according to item 1 characterized in that the formulation contains 2 to 50 % (by weight) of oleyl alcohol, preferably 5 to 20 % 3.
  • Pharmaceutical formulation according to at least one of the preceding items characterized in that the formulation contains 2 to 50 % (by weight) of cetearyl octanoate, preferably 3 to 20 %.
  • composition according to at least one of the preceding items, characterized in that the formulation 2 to 50 % (by weight) of vegetable oil, preferably 5 to 20 %.
  • composition according to item 1 furthermore containing d) propylene glycol e) glycerol.
  • composition according to item 6 characterized in that the formulation contains 3 to 15 % (by weight) of oleyl alcohol, preferably 5 to 10 %.
  • composition according to item 6 characterized in that the formulation contains 2 to 15 % (by weight) of cetearyl octanoate, preferably 3 to
  • composition according to item 6 characterized in that the formulation contains 3 to 15 % (by weight) of vegetable oil, preferably 4 to 6 %.
  • composition according to item 6 characterized in that the formulation contains 4 to 10 % (by weight) of glycerol (85%), preferably 8%. 11. Pharmaceutical formulation according to item 6, characterized in that the formulation 4 to 10 % (by weight) of propylene glycol, preferably 8%.
  • composition according to at least one of items 6-11 , characterized in that the formulation contains furthermore medium-chained triglycerides, mineral oil, cyclomethicone, stearyl alcohol, butylated hydroxytoluene, macrogolglycerolhydroxystearate, povidone, acrylic acid copolymer, hydroxyethylcellulose, acrylic acid, trometamol.
  • composition according to item 1 furthermore containing d) silicon dioxide.
  • Pharmaceutical formulation according to item 1 furthermore containing d) aluminium stearate.
  • composition according to item 13 and 14 characterized in that the formulation contains 10 to 40 % (by weight) of oleyl alcohol, preferably 15 to 30 %. 16. Pharmaceutical formulation according to item 13 and 14, characterized in that the formulation contains 5 to 40 % (by weight) of cetearyl octanoate, preferably 10 to 30 %.
  • composition according to item 13 and 14 characterized in that the formulation contains 10 to 30 % (by weight) of vegetable oil, preferably 15 to 20 %.
  • composition according to item 14 characterized in that the formulation contains 3 to i ⁇ % (by weight) of silicone dioxide, preferably 4 to 5 %.
  • composition according to item 14 characterized in that the formulation contains 2 to 8 % (by weight) of aluminium stearate, preferably 3 to
  • composition according to at least one of items 13-19 characterized in that the formulation contains furthermore medium-chained triglycerides, mineral oil, cyclomethicone, or mixtures thereof.
  • composition according to item 1 furthermore containing d) mineral oil.
  • composition according to item 21 characterized in that the formulation contains 10 to 50 % (by weight) of oleyl alcohol, preferably 10 to 40 %.
  • composition according to item 21 characterized in that the formulation contains 10 to 50 % (by weight) of cetearyl octanoate, preferably 20 to 40 %.
  • composition according to item 21 characterized in that the formulation contains 10 to 50 % (by weight) of vegetable oil, preferably 16 to
  • composition according to item 21 characterized in that the formulation contains 2 to 15 % (by weight) of mineral oil, preferably 4 to 15 %.
  • composition according to at least one of items 21-25 characterized in that the formulation furthermore contains medium-chained triglycerides, cyclomethicone, or mixtures thereof.
  • composition according to item 1 furthermore containing d) propylene glycol, e) glycerol, f) a propellant.
  • composition according to item 27 characterized in that the formulation contains 2 to 15 % (by weight) of oleyl alcohol, preferably 3 to 10 %.
  • composition according to item 27 characterized in that the formulation contains 2 to 10 % (by weight) of cetearyl octanoate, preferably 3 to 5 %.
  • composition according to item 27 characterized in that the formulation contains 2 to 10 % (by weight) of vegetable oil, preferably 3 to 5 %.
  • composition according to item 27 characterized in that the formulation contains 2 to 10 % (by weight) of glycerol (85%), preferably 4 to 8 %.
  • formulation contains 2 to 10 % (by weight) of propylene glycol, preferably 4 to 10 %.
  • composition according to at least one of items 27-32 characterized in that the formulation contains 2 to 10 % (by weight) of propellant, preferably 6 to 8 %.
  • propellants are hydrocarbons such as propane, butane, isobutane or a mixture of these; a hydrofluoroalkane such as heptafluoropropane or tetrafluoroethane, dimethylether, or mixtures thereof.
  • compositions according to at least one of items 27-34 characterized in that the formulation contains furthermore macrogolglycerolhydroxystearate, macrogol-400-stearate, methylcellulose, xanthan gum, parts of these or mixtures thereof.
  • compositions according to any of items 1-35 characterized in that the solubility of at least one pharmaceutically active compound in water is 20 mg/l at 20 0 C or less.
  • composition according to item 36 characterized in that the solubility of at least one pharmaceutically active compound in water is 2 mg/l at 2O 0 C or less.
  • the pharmaceutically active compound includes glucocorticosteroids, steroids, calcineurin inhibitors, vitamin D analoques, retinoids, immunosuppressants, antimycotics, antiinfectives, estrogens, androgens, fumaric acid esters or a glucocorticoid including but not limited to betametasone, clobetasol, dexametasone, prednicarbate, clocortolone, mometasone, methylprednisolone, esters and salts thereof or an antimycotic drug substance, including but not limited to bifonazole, clotrimazole, itraconazole, fluconazole, terbinafine or a vitamin D analogue including but not limited to Calcipotriol, Calcitriol,
  • a corticosteroid such as prednisone or fludrocortisone
  • a calcineurin inhibitor such as tacrolimus or pimecrolimus.
  • Soybean Oil (vegetable oils) 6,00 4,00 4,00 4,00 4,00 4,00 3,00-15,00
  • Acrylic acid copolymer 0,30 - 0,30 0,30 - 0,10-1,00 Hydroxyethylcellulose - 1,50 - - - 0,10-1,00
  • Trometamol solution 10% to pH 7 to pH 7 to pH 7 to pH 7 to pH 7 to pH 7 to pH 7,0
  • Soybean Oil (vegetable oils) 3,00 5,00 2,00 - 5,00 2,00-10,00
  • Glyceryl Stearate - 0,50 0,50 0,50 0,50 0,50-2,00
  • Methylcellulose 0,10 0,10 0,10 0,15 0,10 0,05-1,00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne une préparation contenant un composé pharmaceutiquement actif difficilement soluble dans l'eau à une concentration de 50 mg pour au moins 100 g de préparation. La solubilité est obtenue par un mélange de solvants, décrits dans le présent document. La préparation décrite dans le présent document peut être, en outre, utilisée comme préparation de base pour la création d'une crème, d'un onguent, d'un aérosol, d'une mousse ou d'un oléogel.
PCT/EP2008/006067 2007-07-09 2008-07-09 Composition pharmaceutique pour application topique de composés difficilement solubles WO2009007137A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU2008274507A AU2008274507A1 (en) 2007-07-09 2008-07-09 Pharmaceutical composition for topical application of poorly soluble compounds
JP2010515429A JP2010532778A (ja) 2007-07-09 2008-07-09 低溶解度化合物を局所適用するための医薬組成物
CA 2692482 CA2692482A1 (fr) 2007-07-09 2008-07-09 Composition pharmaceutique pour application topique de composes difficilement solubles
CN200880023951A CN101730522A (zh) 2007-07-09 2008-07-09 用于局部施用难溶性化合物的药物组合物
BRPI0814043A BRPI0814043A2 (pt) 2007-07-09 2008-07-09 composição farmacêutica para aplicação tópica de compostos pouco solúveis
EP08785020A EP2182918A2 (fr) 2007-07-09 2008-07-09 Composition pharmaceutique pour application topique de composés faiblement solubles
IL202178A IL202178A0 (en) 2007-07-09 2009-11-17 Pharmaceutical composition for topical application of poorly soluble compounds

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US94855407P 2007-07-09 2007-07-09
EP07013369A EP2016935A1 (fr) 2007-07-09 2007-07-09 Composition pharmaceutique pour application topique de composés faiblement solubles
US60/948,554 2007-07-09
EP07013369.9 2007-07-09

Publications (2)

Publication Number Publication Date
WO2009007137A2 true WO2009007137A2 (fr) 2009-01-15
WO2009007137A3 WO2009007137A3 (fr) 2009-04-09

Family

ID=38521635

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/006067 WO2009007137A2 (fr) 2007-07-09 2008-07-09 Composition pharmaceutique pour application topique de composés difficilement solubles

Country Status (14)

Country Link
US (1) US8282909B2 (fr)
EP (2) EP2016935A1 (fr)
JP (1) JP2010532778A (fr)
KR (1) KR20100065141A (fr)
CN (1) CN101730522A (fr)
AR (1) AR067479A1 (fr)
AU (1) AU2008274507A1 (fr)
BR (1) BRPI0814043A2 (fr)
CA (1) CA2692482A1 (fr)
IL (1) IL202178A0 (fr)
RU (1) RU2010104043A (fr)
SG (1) SG183006A1 (fr)
TW (1) TW200911301A (fr)
WO (1) WO2009007137A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210260077A1 (en) * 2020-02-25 2021-08-26 Labomed Pharmaceutical Company S.A. Oral solutions comprising fludrocortisone acetate

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100249060A1 (en) * 2009-02-23 2010-09-30 Smith Jan G Topical formulation of low level clobetasol propionate for treating disorders of the skin and mucous membranes
CN105708842B (zh) * 2014-12-03 2020-06-26 四川海思科制药有限公司 一种外用药物组合物
CN107157919B (zh) * 2016-03-08 2019-12-27 上海通用药业股份有限公司 一种用于治疗银屑病的半固体制剂的制备方法
CN107157918B (zh) * 2016-03-08 2019-12-27 上海通用药业股份有限公司 一种用于银屑病治疗的半固体制剂的制备方法
CN107157920B (zh) * 2016-03-08 2019-12-27 上海通用药业股份有限公司 一种包含维生素d或其衍生物的半固体制剂的制备方法
CN107157917B (zh) * 2016-03-08 2019-12-27 上海通用药业股份有限公司 一种用于治疗银屑病的软膏的制备方法
WO2019233722A1 (fr) * 2018-06-08 2019-12-12 Almirall, S.A. Composition pharmaceutique comprenant du tacrolimus
WO2020152193A1 (fr) 2019-01-22 2020-07-30 Akribes Biomedical Gmbh Modificateurs sélectifs du récepteur de glucocorticoïdes pour le traitement de la mauvaise cicatrisation de plaies cutanées
CN116602914B (zh) * 2023-07-05 2024-02-13 江苏知原药业股份有限公司 一种皮炎用乳膏及其生产工艺及其生产设备

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991008733A1 (fr) * 1989-12-20 1991-06-27 Schering Corporation Bases stables de creme et de lotion pour medicaments lipophiles
WO1995025523A1 (fr) * 1994-03-23 1995-09-28 Yungjin Pharmaceutical Co., Ltd. Nouvelle composition pharmaceutique pour dermatoses
WO2003077885A2 (fr) * 2002-03-12 2003-09-25 Neurogesx, Inc. Preparations a base libre d'anesthesiques locaux
WO2003082827A1 (fr) * 2002-04-02 2003-10-09 Schering Aktiengesellschaft Derives de quinoleine et d'isoquinoleine, procede de production de ces derives et leur utilisation comme agents anti-inflammatoires
EP1537857A1 (fr) * 2003-12-03 2005-06-08 Agis Industries (1983) Ltd Compositions à usage topique comprenant de la mupirocine, procédé de préparation et applications.
US20060241175A1 (en) * 2002-09-27 2006-10-26 Joseph Schwarz Vehicle for topical delivery of anti-inflammatory compounds

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT786986E (pt) * 1994-10-26 2002-07-31 Novartis Ag Formulacoes farmaceuticas
US5567420A (en) * 1994-11-16 1996-10-22 Mceleney; John Lotion which is temporarily colored upon application
DE19722196C1 (de) * 1997-05-27 1998-10-22 Karl Engelhard Fabrik Pharm Pr Insektenvertreibungsmittel
GB9715751D0 (en) * 1997-07-26 1997-10-01 Ciba Geigy Ag Formulations
DE10141258B4 (de) * 2001-08-23 2004-09-23 Beiersdorf Ag Kosmetische und dermatologische Zubereitung und ihre Verwendung
DE10143960A1 (de) * 2001-09-07 2003-03-27 Basf Ag Kosmetische und dermatologische Zubereitungen in Stiftform, enthaltend ein aminosubstituiertes Hydroxybenzophenon
US7378479B2 (en) * 2002-09-13 2008-05-27 Lubrizol Advanced Materials, Inc. Multi-purpose polymers, methods and compositions
GB0307866D0 (en) * 2003-04-04 2003-05-14 Novartis Ag Pharmaceutical composition
US20040265249A1 (en) * 2003-06-24 2004-12-30 Desert Whale Jojoba Company Composition for protecting skin from damaging effects of ultraviolet light
US7417056B2 (en) * 2004-11-12 2008-08-26 Schering Ag 5-substituted quinoline and isoquinoline derivatives, a process for their production and their use as anti-inflammatory agents
DE102004055633A1 (de) * 2004-11-12 2006-05-18 Schering Ag 5-substituierte Chinolin- und Isochinolin-Derivate, ein Verfahren zu ihrer Herstellung und ihre Verwendung als Entzündungshemmer

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991008733A1 (fr) * 1989-12-20 1991-06-27 Schering Corporation Bases stables de creme et de lotion pour medicaments lipophiles
WO1995025523A1 (fr) * 1994-03-23 1995-09-28 Yungjin Pharmaceutical Co., Ltd. Nouvelle composition pharmaceutique pour dermatoses
WO2003077885A2 (fr) * 2002-03-12 2003-09-25 Neurogesx, Inc. Preparations a base libre d'anesthesiques locaux
WO2003082827A1 (fr) * 2002-04-02 2003-10-09 Schering Aktiengesellschaft Derives de quinoleine et d'isoquinoleine, procede de production de ces derives et leur utilisation comme agents anti-inflammatoires
US20060241175A1 (en) * 2002-09-27 2006-10-26 Joseph Schwarz Vehicle for topical delivery of anti-inflammatory compounds
EP1537857A1 (fr) * 2003-12-03 2005-06-08 Agis Industries (1983) Ltd Compositions à usage topique comprenant de la mupirocine, procédé de préparation et applications.

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
GALLARATE M ET AL: "On the stability of ascorbic acid in emulsified systems for topical and cosmetic use" INTERNATIONAL JOURNAL OF PHARMACEUTICS, AMSTERDAM, NL, vol. 188, no. 2, 25 October 1999 (1999-10-25), pages 233-241, XP002228583 ISSN: 0378-5173 *
See also references of EP2182918A2 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210260077A1 (en) * 2020-02-25 2021-08-26 Labomed Pharmaceutical Company S.A. Oral solutions comprising fludrocortisone acetate
US11771706B2 (en) * 2020-02-25 2023-10-03 Labomed Pharmaceutical Company S.A. Oral solutions comprising fludrocortisone acetate

Also Published As

Publication number Publication date
WO2009007137A3 (fr) 2009-04-09
SG183006A1 (en) 2012-08-30
JP2010532778A (ja) 2010-10-14
CN101730522A (zh) 2010-06-09
EP2182918A2 (fr) 2010-05-12
CA2692482A1 (fr) 2009-01-15
IL202178A0 (en) 2010-06-16
US8282909B2 (en) 2012-10-09
RU2010104043A (ru) 2011-08-20
BRPI0814043A2 (pt) 2017-05-16
EP2016935A1 (fr) 2009-01-21
KR20100065141A (ko) 2010-06-15
AR067479A1 (es) 2009-10-14
TW200911301A (en) 2009-03-16
US20090016969A1 (en) 2009-01-15
AU2008274507A1 (en) 2009-01-15

Similar Documents

Publication Publication Date Title
US8282909B2 (en) Pharmaceutical composition for topical application of poorly soluble compounds
US10905697B2 (en) Topical formulations comprising a steroid
RU2621615C2 (ru) Фармацевтическая композиция, содержащая луликоназол
AU2023266295A1 (en) Therapeutic topical compositions of apremilast
WO2005000287A1 (fr) Preparation externe permettant de traiter les pieds d'un athlete
CN110869020B (zh) 度他雄胺的局部用组合物
AP197A (en) Pharmaceutical formulations for treatment of virus infections of the skin containing penciclovir.
JP2023536102A (ja) Ｊａｋ阻害剤およびラウレス－４を含有する局所配合物
WO2015044879A1 (fr) Composition topique d'halobétasol sans propulsif, à pulvériser
US11185504B2 (en) Transdermal non-aqueous nanoemulgels for systemic delivery of aromatase inhibitor
EP4114358A1 (fr) Formulations pharmaceutiques topiques d'un depsipeptide cyclique
JP2015205877A (ja) 抗真菌剤とステロイド系薬剤とを含有する外用医薬組成物
JP2022069434A (ja) 組成物
JP2016204371A (ja) 皮膚用の医薬組成物

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880023951.3

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08785020

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2008785020

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2152/MUMNP/2009

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 581310

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2008274507

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2008274507

Country of ref document: AU

Date of ref document: 20080709

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2692482

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2010010028

Country of ref document: EG

WWE Wipo information: entry into national phase

Ref document number: MX/A/2010/000220

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 20107000476

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2010515429

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2010104043

Country of ref document: RU

ENP Entry into the national phase

Ref document number: PI0814043

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100107